Literature DB >> 8435202

Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.

A S Planting1, G Stoter, J Verweij.   

Abstract

34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine). Most patients received 3 x 50 mg daily, while in 11 patients the dose could be escalated to 4 x 50 mg daily. Nausea and vomiting were the most frequent side-effects occurring in all but 3 patients, nephrotoxicity was observed in 11 patients. Leucocytosis was observed in 24 and thrombocytosis in 17 patients. 28 patients are evaluable for response. 1 patient obtained a partial response of liver metastases for a duration of 8 months. 3 patients had stable disease while 24 progressed during treatment. We conclude that miltefosine in this dose and schedule has limited activity in colorectal cancer.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8435202     DOI： 10.1016/s0959-8049(05)80142-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  15 in total

1.  Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.

Authors:  Stefan R Vink; Jan H M Schellens; Wim J van Blitterswijk; Marcel Verheij
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

Review 2.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system.

Authors:  C Cabaner; C Gajate; A Macho; E Muñoz; M Modolell; F Mollinedo
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

4.  Minimal Cerebrospinal Fluid Concentration of Miltefosine despite Therapeutic Plasma Levels during the Treatment of Amebic Encephalitis.

Authors:  Marguerite L Monogue; Durward Watson; Julie S Alexander; Dominick Cavuoti; Laura M Doyle; Michael Zhuo Wang; Bonnie C Prokesch
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

5.  Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.

Authors:  Y Le Fichoux; D Rousseau; B Ferrua; S Ruette; A Lelièvre; D Grousson; J Kubar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 6.  Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.

Authors:  Shin Ogita; Patricia Lorusso
Journal:  Target Oncol       Date:  2011-05-06       Impact factor: 4.493

7.  Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs.

Authors:  Michael Fiegl; Lars H Lindner; Matthias Juergens; Hansjoerg Eibl; Wolfgang Hiddemann; Jan Braess
Journal:  Cancer Chemother Pharmacol       Date:  2007-10-06       Impact factor: 3.333

8.  Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.

Authors:  I Fichtner; R Zeisig; H Naundorf; S Jungmann; D Arndt; G Asongwe; J A Double; M C Bibby
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.

Authors:  J M Terwogt; I A Mandjes; H Sindermann; J H Beijnen; W W ten Bokkel Huinink
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

10.  Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy.

Authors:  Guido Henke; Lars H Lindner; Michael Vogeser; Hans-Jörg Eibl; Jürgen Wörner; Arndt C Müller; Michael Bamberg; Kirsten Wachholz; Claus Belka; Verena Jendrossek
Journal:  Radiat Oncol       Date:  2009-10-23       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.